Trial Profile
Phase I Evaluation of the Safety of PS 341 in the Treatment of Recurrent Gliomas
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Antiepileptic drugs
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma
- Focus Adverse reactions
- 23 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 10 Jul 2007 Status changed from recruiting to completed.
- 22 Aug 2005 New trial record.